A detailed history of Ubs Group Ag transactions in Jan One Inc. stock. As of the latest transaction made, Ubs Group Ag holds 728 shares of JAN stock, worth $1,630. This represents 0.0% of its overall portfolio holdings.

Number of Shares
728
Previous 10,291 92.93%
Holding current value
$1,630
Previous $5,000 80.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$0.5 - $2.88 $4,781 - $27,541
-9,563 Reduced 92.93%
728 $1,000
Q4 2023

Feb 09, 2024

BUY
$0.3 - $0.66 $3,087 - $6,792
10,291 New
10,291 $5,000
Q2 2023

Aug 11, 2023

SELL
$0.87 - $1.2 $3,433 - $4,736
-3,947 Reduced 90.86%
397 $0
Q1 2023

May 12, 2023

BUY
$1.07 - $1.77 $2,546 - $4,212
2,380 Added 121.18%
4,344 $4,000
Q4 2022

Feb 08, 2023

BUY
$1.37 - $2.12 $2,690 - $4,163
1,964 New
1,964 $2,000
Q2 2022

Aug 10, 2022

SELL
$2.0 - $4.07 $1,586 - $3,227
-793 Reduced 20.45%
3,084 $8,000
Q1 2022

May 16, 2022

BUY
$2.5 - $4.25 $955 - $1,623
382 Added 10.93%
3,877 $14,000
Q4 2021

Feb 14, 2022

BUY
$3.86 - $6.65 $13,490 - $23,241
3,495 New
3,495 $14,000
Q3 2021

Nov 15, 2021

SELL
$5.98 - $8.0 $49,514 - $66,240
-8,280 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$5.9 - $9.46 $32,916 - $52,777
5,579 Added 206.55%
8,280 $65,000
Q1 2021

May 12, 2021

SELL
$4.47 - $12.99 $11,863 - $34,475
-2,654 Reduced 49.56%
2,701 $23,000
Q4 2020

Feb 11, 2021

BUY
$3.5 - $5.44 $18,742 - $29,131
5,355 New
5,355 $26,000
Q3 2020

Nov 12, 2020

SELL
$3.07 - $7.79 $10,398 - $26,384
-3,387 Closed
0 $0
Q2 2020

Jul 31, 2020

BUY
$2.1 - $3.67 $884 - $1,545
421 Added 14.19%
3,387 $11,000
Q1 2020

May 01, 2020

SELL
$2.05 - $4.12 $3,946 - $7,931
-1,925 Reduced 39.36%
2,966 $7,000
Q4 2019

Feb 14, 2020

BUY
$2.24 - $3.94 $10,955 - $19,270
4,891 New
4,891 $14,000

Others Institutions Holding JAN

About JanOne Inc.


  • Ticker JAN
  • Exchange NASDAQ
  • Sector Industrials
  • Industry Waste Management
  • Shares Outstandng 3,150,230
  • Market Cap $7.06M
  • Description
  • JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. ...
More about JAN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.